Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Olaparib for Metastatic Castration-Resistant Prostate Cancer

by Burgents, Joseph , Hussain, Maha , Shore, Neal , Sandhu, Shahneen , Chi, Kim N , Agarwal, Neeraj , Twardowski, Przemyslaw , Mehra, Niven , Fizazi, Karim , Kohlmann, Alexander , Saad, Fred , de Bono, Johann , Adelman, Carrie A , Kang, Jinyu , Wu, Wenting , Olmos, David , Goessl, Carsten , Sartor, Oliver , Thiery-Vuillemin, Antoine , Mateo, Joaquin

in Adenosine / Aged / Aged, 80 and over / Androstenes - adverse effects / Androstenes - therapeutic use / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Ataxia Telangiectasia Mutated Proteins - genetics / Benzamides / Biomarkers / BRCA1 protein / BRCA2 protein / Cancer therapies / Castration / Deoxyribonucleic acid / DNA / DNA repair / Genes / Genes, BRCA1 / Genes, BRCA2 / Homologous recombination / Homologous recombination repair / Humans / Loss of Function Mutation / Male / Metastases / Metastasis / Middle Aged / Nausea / Neoplasm Metastasis - drug therapy / Nitriles / Pain / Phenylthiohydantoin - adverse effects / Phenylthiohydantoin - analogs & derivatives / Phenylthiohydantoin - therapeutic use / Phthalazines - adverse effects / Phthalazines - therapeutic use / Piperazines - adverse effects / Piperazines - therapeutic use / Poly(ADP-ribose) polymerase / Poly(ADP-ribose) Polymerase Inhibitors - adverse effects / Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use / Progression-Free Survival / Prostate cancer / Prostatic Neoplasms, Castration-Resistant - drug therapy / Prostatic Neoplasms, Castration-Resistant - genetics / Prostatic Neoplasms, Castration-Resistant - mortality / Prostatic Neoplasms, Castration-Resistant - pathology / Ribose / Sensitivity analysis / Statistical analysis / Survival / Tumors

2020

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020

Confirm

Do you wish to request the book?

Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Burgents, Joseph,

Hussain, Maha,

Shore, Neal,

Sandhu, Shahneen,

Chi, Kim N,

Agarwal, Neeraj,

Twardowski, Przemyslaw,

Mehra, Niven,

Fizazi, Karim,

Kohlmann, Alexander,

Saad, Fred,

de Bono, Johann,

Adelman, Carrie A,

Kang, Jinyu,

Wu, Wenting,

Olmos, David,

Goessl, Carsten,

Sartor, Oliver,

Thiery-Vuillemin, Antoine,

Mateo, Joaquin

2020

Overview

Up to 30% of patients with metastatic castration-resistant prostate cancer have deleterious mutations in genes involved in homologous recombination repair of DNA damage. The use of the PARP inhibitor olaparib in such patients was associated with longer progression-free survival and a longer time to pain progression than control therapy.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adenosine

/ Aged

/ Aged, 80 and over

/ Androstenes - adverse effects

/ Androstenes - therapeutic use

/ Antineoplastic Agents - adverse effects

/ Antineoplastic Agents - therapeutic use